Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Citi maintains buy on BridgeBio stock, raises target to $46

EditorNatashya Angelica
Published 02/23/2024, 01:02 PM
Updated 02/23/2024, 01:02 PM
© Reuters.

On Friday, Citi reaffirmed its positive stance on BridgeBio Pharma (NASDAQ:BBIO), reflected in a raised price target on the company's stock. The new target of $46, up from $42, comes with a maintained Buy rating. The adjustment follows BridgeBio's announcement of its fourth quarter and full-year 2023 financial results, along with updates on its pipeline programs and key milestones.

BridgeBio's recent financial disclosure and pipeline progress have been a focal point for investors, particularly regarding acoramidis, its treatment for a condition known as transthyretin (TTR) amyloidosis. Citi anticipates that acoramidis will receive approval by the scheduled PDUFA date of November 29, 2024. Despite competition, notably from a pivotal trial update of Amvuttra, a competing treatment, Citi believes acoramidis is well-positioned to capture a significant share of the TTR market.

The financial institution also highlighted the reiteration of timelines for other significant updates within BridgeBio's development pipeline. This includes the first patient dosing of infigratinib in children with hypochondroplasia expected in 2024, and the release of top-line Phase 3 CALIBRATE study results for encaleret, intended for autosomal dominant hypocalcemia type 1 (ADH1), projected for 2025.

Moreover, BridgeBio is anticipated to complete enrollment for its BBP-418 trial in patients with limb-girdle muscular dystrophy (LGMD) within the current year. This milestone is part of the company's broader efforts to advance its portfolio of treatments for genetic diseases, with several key developments expected to unfold in the near future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.